Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
Open Access
- 9 May 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 94 (11), 1592-1598
- https://doi.org/10.1038/sj.bjc.6603129
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Docetaxel administration schedule: From fever to tears? A review of randomised studiesEuropean Journal of Cancer, 2005
- LIMITATIONS IN THE USE OF SERUM PROSTATE SPECIFIC ANTIGEN LEVELS TO MONITOR PATIENTS AFTER TREATMENT FOR PROSTATE CANCERJournal of Urology, 2005
- Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarkerCancer Letters, 2004
- Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2004
- Therapy Control in Oncology by Circulating NucleosomesAnnals of the New York Academy of Sciences, 2004
- ERK inhibitor PD98059 enhances docetaxel‐induced apoptosis of androgen‐independent human prostate cancer cellsInternational Journal of Cancer, 2003
- Activity of Docetaxel With or Without Estramustine Phosphate Versus Mitoxantrone in Androgen Dependent and Independent Human Prostate Cancer XenograftsJournal of Urology, 2003
- SERIAL TISSUE POLYPEPTIDE SPECIFIC ANTIGEN DETERMINATIONS IN THE FOLLOWUP OF HORMONE TREATED CARCINOMA OF THE PROSTATEJournal of Urology, 1997
- Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate CancerJNCI Journal of the National Cancer Institute, 1996
- Vinorelbine: an overviewCancer Treatment Reviews, 1996